Want to see SE:ACE full AI Analyst Report?
ACE Stock Chart & Stats
kr3.17
-kr0.11(-3.47%)
At close: 4:00 PM EST
kr3.17
-kr0.11(-3.47%)
Day’s Range― - ―
52-Week Rangekr0.46 - kr5.23
Previous CloseN/A
Volume171.87K
Average Volume (3M)1.75M
Market Cap
kr67.30M
Enterprise Valuekr371.41M
Total Cash (Recent Filing)kr33.89M
Total Debt (Recent Filing)kr689.00K
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding133,535,460
10 Day Avg. Volume1,883,755
30 Day Avg. Volume1,753,338
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.67
Price to Sales (P/S)0.00
P/FCF Ratio-5.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.25
Revenue Forecast (FY)kr89.63M
Bulls Say, Bears Say
Bulls Say
Niche Product / Clinical NeedAscelia’s lead candidate is an oral liver‑MRI contrast targeting patients with severe renal impairment and the company focuses on orphan and hospital specialty medicines. This concentration addresses a durable, clinical unmet need and creates a narrow commercial niche with less mass‑market competition and clearer go‑to‑market targeting over months.
Low Financial LeverageTrailing leverage is minimal (debt-to-equity ~0.01), which materially reduces refinancing and interest‑rate risk while preserving strategic flexibility. For a pre-revenue biotech this durable low‑debt profile lowers the chance of near‑term insolvency and supports continued R&D or partner negotiations without high fixed financing costs.
Improving Cash Burn TrendOperating and free cash flow remain negative, but management reports material improvement versus 2022–2023. A sustained reduction in burn rate extends runway, reduces immediate financing pressure, and indicates operational discipline—an enduring positive if the trend continues through upcoming development and regulatory milestones.
Bears Say
No Revenue / Persistent LossesThe company remains pre‑revenue with repetitive, sizable net losses (TTM ~71m). Without product sales, profitability depends on successful approval/commercial deals; this structural lack of revenue implies ongoing capital needs, limited visibility to sustainable margins, and elevated execution risk over the next several months.
Weak Cash GenerationOperating and free cash flow are persistently negative (~-71m TTM), signaling weak internal cash generation. Even with burn improvement, continued outflows will require recurrent financing or partner funding, increasing dilution risk and constraining long‑term planning, R&D prioritization, and commercial preparedness.
Limited Internal Commercial CapacityA very small headcount (11 employees) and stated reliance on partnerships for commercialization indicate limited internal scale to launch and sustain a specialty product. This creates durable execution and margin dependence on third parties, reducing company control over timing, pricing, and market access outcomes.
Ascelia Pharma AB News
ACE FAQ
What was Ascelia Pharma AB’s price range in the past 12 months?
Ascelia Pharma AB lowest stock price was kr0.46 and its highest was kr5.23 in the past 12 months.
What is Ascelia Pharma AB’s market cap?
Ascelia Pharma AB’s market cap is kr67.30M.
When is Ascelia Pharma AB’s upcoming earnings report date?
Ascelia Pharma AB’s upcoming earnings report date is Aug 20, 2026 which is in 25 days.
How were Ascelia Pharma AB’s earnings last quarter?
Ascelia Pharma AB released its earnings results on May 12, 2026. The company reported -kr0.129 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.129.
Is Ascelia Pharma AB overvalued?
According to Wall Street analysts Ascelia Pharma AB’s price is currently Overvalued.
Does Ascelia Pharma AB pay dividends?
Ascelia Pharma AB does not currently pay dividends.
What is Ascelia Pharma AB’s EPS estimate?
Ascelia Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ascelia Pharma AB have?
Ascelia Pharma AB has 133,535,460 shares outstanding.
What happened to Ascelia Pharma AB’s price movement after its last earnings report?
Ascelia Pharma AB reported an EPS of -kr0.129 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.372%.
Which hedge fund is a major shareholder of Ascelia Pharma AB?
Currently, no hedge funds are holding shares in SE:ACE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ascelia Pharma AB
Ascelia Pharma AB (publ) is a Swedish biotechnology company concentrating on the development of orphan drugs for cancer treatment. The firm is currently progressing Mangoral, an innovative non-gadolinium contrast agent, through Phase 3 clinical trials for magnetic resonance imaging (MRI) of the liver. Furthermore, it is advancing Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 development for gastric cancer therapy. Ascelia Pharma has also entered into a clinical collaboration agreement with Taiho Oncology, Inc. to develop Oncoral in combination with LONSURF. The company was established in 2000 and has its headquarters situated in Malmö, Sweden.
Technical Analysis
Xbrane Biopharma AB
―
Isofol Medical AB
―
Guard Therapeutics International AB
―
Immunicum AB
―
Cantargia AB
―